CL 118326
CL 118326 is a potent, selective, competitive inhibitor of mammalian pancreatic phospholipase A2 (PLA2) and a weak antagonist of platelet-activating factor receptor (PAF receptor). CL 118326 competitively inhibits mammalian pancreatic PLA2 (porcine: IC50 = 1.55 μg/mL), and shows no activity against snake venom or bee venom PLA2. CL 118326 inhibits PAF-induced and thrombin-induced platelet aggregation, as well as the release of leukotriene (LTC4) and histamine from basophil-enriched leukocytes. CL 118326 can be used for research on inflammation and allergic reactions.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 97012-61-8
- Formule: C28H58INO3S
- Masse moléculaire:615.73
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
CL 118326 (5 min) inhibits thrombin-induced (IC50 = 7.9 μM) and PAF-induced (IC50 = 5.8 μM) rabbit platelet aggregation, but does not inhibit aggregation induced by arachidonic acid or ADP, and exhibits no PAF agonist activity[1].
CL 118326 (70 min) inhibits histamine and LTC4 release from human basophil-enriched leukocytes stimulated by antigens and ionophores, with IC50 values ranging from 1.36 to 2.34 μg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hartly (male, 250-350 g)[1]
-
Dosage:10 μg; 20 μg
-
Administration:i.d.; single coinjection with PLA2
-
Result:Reduced porcine pancreatic PLA2-induced skin lesion size by 60.4% (from 83.0 mm2 to 32.8 mm2) and 51.0% (from 36.4 mm2 to 17.0 mm2) in one experiment, and by 84.4% (from 124.0 mm2 to 19.3 mm2) and 87.2% (from 56.2 mm2 to 7.2 mm2) in a second experiment, for 50-unit and 25-unit PLA2 challenges respectively.
Reduced lesion size relative to controls across multiple PLA2 dose levels at 20 μg.
Chemical Information
-
CAS No. 97012-61-8
-
Masse moléculaire 615.73
-
Formule C28H58INO3S
-
SMILES
O=C(C)OC(CCSCCC[N+](C)(C)C)COCCCCCCCCCCCCCCCC.[I-]
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CL 118326 Related Classifications
HY-182434 Related Classifications
Powered by Bioz